The Clinical Prognostic Risk Stratification System for HIV Infected Hepatocellular Carcinoma

Yifan Chen,Han Zhao,Yao Wang,Bo Liu,Zhimin Chen,Yu Tao,Yang Xun,Hua Yang,Rongqiu Liu,Lizhi Feng,Xinhua Liu,Hengjing Li,Sibo Wang,Baolin Liao,Dong Zhao,Haolan He,Hua You
DOI: https://doi.org/10.1016/j.clinre.2024.102479
IF: 3.189
2024-01-01
Clinics and Research in Hepatology and Gastroenterology
Abstract:BACKGROUND:Patients with human immunodeficiency virus (HIV) are more susceptible to liver cancer because of their compromised immune system. There is no specific prognostic model for HIV-infected hepatocellular carcinoma (HCC) patients. METHODS:Clinical data of 85 patients with HIV-infected HCC was divided into a 7:3 ratio for training and internal validation sets, while the data of 23 patients with HIV-infected HCC was served as the external validation set. Data of 275 HIV-negative HCC patients was considered as external HIV-negative validation set. Variables associated with overall survival (OS) in the training set were used to develop the HIV-infected HCC prognosis (HIHP) model. The model was tested in the internal and external validation sets. The predictive accuracy of the model was assessed with conventional HIV-negative HCC prognostic scoring systems. RESULTS:In the training set, variables independently associated with OS in multivariable analysis were organ involvement and tumor number. The HIHP model demonstrated a significant association with OS in the training set, with a median OS of 13 months for low risk, 7 months for medium risk, and 3 months for high risk (p < 0.001). The HIHP model showed a significant association with OS, and exhibited greater discriminative abilities compared to conventional HIV-negative HCC prognostic models both in the internal and external validation sets. In the external HIV-negative validation set, the HIHP model did not show better discrimination than conventional HIV-negative HCC scores. CONCLUSION:The new model presented in the work provided a more accurate prognostic prediction of OS in HIV-infected HCC patients. However, the model is not applicable to patients with HIV-negative HCC.
What problem does this paper attempt to address?